CL2015003491A1 - Compuestos químicos. - Google Patents

Compuestos químicos.

Info

Publication number
CL2015003491A1
CL2015003491A1 CL2015003491A CL2015003491A CL2015003491A1 CL 2015003491 A1 CL2015003491 A1 CL 2015003491A1 CL 2015003491 A CL2015003491 A CL 2015003491A CL 2015003491 A CL2015003491 A CL 2015003491A CL 2015003491 A1 CL2015003491 A1 CL 2015003491A1
Authority
CL
Chile
Prior art keywords
chemical compounds
cancer
pirido
indol
prevention
Prior art date
Application number
CL2015003491A
Other languages
English (en)
Spanish (es)
Inventor
Nadim Akhtar
Robert Hugh Bradbury
David Buttar
Gordon Stuart Currie
Savi Christopher De
Craig Samuel Donald
Richard Albert Norman
Matthew Osborne
Alfred Arthur Rabow
Heather Marie Redfearn
Helen Elizabeth Williams
Neda Yavari
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2015003491A1 publication Critical patent/CL2015003491A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2015003491A 2013-05-28 2015-11-27 Compuestos químicos. CL2015003491A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827951P 2013-05-28 2013-05-28
US201361915685P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
CL2015003491A1 true CL2015003491A1 (es) 2016-06-03

Family

ID=50841880

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003491A CL2015003491A1 (es) 2013-05-28 2015-11-27 Compuestos químicos.

Country Status (35)

Country Link
US (4) US9155727B2 (OSRAM)
EP (2) EP3360875A1 (OSRAM)
JP (1) JP6286031B2 (OSRAM)
KR (1) KR20160013198A (OSRAM)
CN (1) CN105229004B (OSRAM)
AP (1) AP2015008858A0 (OSRAM)
AU (1) AU2014272856B2 (OSRAM)
BR (1) BR112015029455A8 (OSRAM)
CA (1) CA2911859A1 (OSRAM)
CL (1) CL2015003491A1 (OSRAM)
CR (1) CR20150629A (OSRAM)
CY (1) CY1120474T1 (OSRAM)
DK (1) DK3004090T3 (OSRAM)
DO (1) DOP2015000274A (OSRAM)
ES (1) ES2654161T3 (OSRAM)
HR (1) HRP20171961T1 (OSRAM)
HU (1) HUE035738T2 (OSRAM)
IL (1) IL242559B (OSRAM)
LT (1) LT3004090T (OSRAM)
ME (1) ME02892B (OSRAM)
MX (1) MX361538B (OSRAM)
NI (1) NI201500167A (OSRAM)
PE (1) PE20160874A1 (OSRAM)
PH (1) PH12015502615A1 (OSRAM)
PL (1) PL3004090T3 (OSRAM)
PT (1) PT3004090T (OSRAM)
RS (1) RS56678B1 (OSRAM)
RU (1) RU2664109C2 (OSRAM)
SG (1) SG11201509393VA (OSRAM)
SI (1) SI3004090T1 (OSRAM)
SM (1) SMT201700589T1 (OSRAM)
TN (1) TN2015000516A1 (OSRAM)
TW (1) TWI653235B (OSRAM)
UY (1) UY35590A (OSRAM)
WO (1) WO2014191726A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CA2909742C (en) 2013-05-17 2020-08-04 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
NZ717629A (en) 2013-10-23 2021-12-24 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
ES2819448T3 (es) 2014-12-18 2021-04-16 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
MX372914B (es) * 2015-06-16 2020-04-27 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
RU2745742C1 (ru) 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
JP6592197B2 (ja) * 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
CN108495628B (zh) 2015-12-09 2022-01-11 伊利诺伊大学评议会 苯并噻吩基选择性雌激素受体下调剂
KR20180095564A (ko) 2015-12-22 2018-08-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도
AU2017213614B2 (en) 2016-02-05 2022-09-01 Inventisbio Llc Selective estrogen receptor degraders and uses thereof
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
EP3449017B1 (en) 2016-04-29 2021-12-22 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
WO2017197904A2 (zh) * 2016-05-08 2017-11-23 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
EP3472159A1 (en) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
SMT201900602T1 (it) 2016-10-24 2019-11-13 Astrazeneca Ab Derivato di 6,7,8,9-tetraidro-3h-pirazolo[4,3-f]isochinolina utile nel trattamento del cancro
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
EP3689873B1 (en) * 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用
CN110536888B (zh) * 2017-06-20 2022-07-26 江苏恒瑞医药股份有限公司 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
IL321733A (en) 2017-10-18 2025-08-01 Novartis Ag Compositions and methods for selective degradation of proteins
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
CN109867659A (zh) * 2017-12-04 2019-06-11 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物的制备方法
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
US11731927B2 (en) * 2018-02-23 2023-08-22 Center For Intelligent Research In Crystal Engineering, S.L. Cocrystals of ubiquinol and compositions comprising them
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
EA202092436A1 (ru) 2018-05-14 2021-05-04 Нувейшн Био Инк. Противораковые соединения, нацеливающие на ядерные гормональные рецепторы
WO2019228443A1 (en) * 2018-05-30 2019-12-05 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Selective estrogen receptor downregulators and uses thereof
CR20230409A (es) 2018-06-21 2023-09-25 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso (divisional expediente 2020-0621)
EA202190146A1 (ru) 2018-07-03 2021-04-27 Те Борд Оф Трастиз Оф Те Юниверсити Оф Иллинойс Активаторы реакции на несложенные белки
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
AU2018454987B2 (en) 2018-12-24 2025-05-29 InventisBio Co., Ltd. Novel salts of selective estrogen receptor degraders
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114302722A (zh) 2019-07-07 2022-04-08 奥列马制药公司 雌激素受体拮抗剂方案
AU2020326691A1 (en) 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
JP2022553833A (ja) * 2019-11-04 2022-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬の塩及び形態
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2022007659A (es) 2019-12-20 2022-07-19 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
EP4089094A4 (en) 2020-01-10 2023-08-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
CN115279370B (zh) 2020-03-05 2025-01-10 C4医药公司 用于brd9的靶向降解的化合物
WO2021178846A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN120267673A (zh) 2020-04-24 2025-07-08 阿斯利康(瑞典)有限公司 用于治疗癌症的剂量方案
KR20230005270A (ko) 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
MX2023001572A (es) * 2020-08-05 2023-05-08 Aizant Drug Res Solutions Private Limited Formas farmaceuticas sólidas de palbociclib.
JP2023551192A (ja) 2020-11-23 2023-12-07 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
EP4351583A4 (en) 2021-06-08 2025-06-04 C4 Therapeutics, Inc. THERAPEUTICS TO DEGRADE MUTANT BRAF
US20250049768A1 (en) * 2021-07-08 2025-02-13 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN117642405A (zh) 2021-07-09 2024-03-01 江苏恒瑞医药股份有限公司 一种三环四氢异喹啉类衍生物的盐型
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
WO2024242504A1 (ko) * 2023-05-25 2024-11-28 주식회사 삼양홀딩스 팔보시클립의 경구용 조성물
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2381497A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
FR2778404B1 (fr) * 1998-05-06 2000-06-30 Hoechst Marion Roussel Inc Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE465161T1 (de) * 2000-03-15 2010-05-15 Sanofi Aventis Deutschland Substituierte beta-carboline mit ikb-kinase hemmender wirkung
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
CA2473441A1 (en) 2002-01-18 2003-07-24 The Genetics Company Inc. Beta-secretase inhibitors
US7655674B2 (en) 2002-04-22 2010-02-02 The Johns Hopkins University Modulators of hedgehog signaling pathways, compositions and uses related thereto
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
CA2533812C (en) * 2003-07-28 2012-12-18 Smithkline Beecham Corporation Substituted cycloalkylidene compounds
DE10335725A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate
CN1910183A (zh) * 2004-01-23 2007-02-07 希龙公司 四氢咔啉化合物作为抗癌药
ES2304010T3 (es) * 2004-03-11 2008-09-01 Actelion Pharmaceuticals Ltd. Derivados de tetrahidropiridoindol.
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
JP2008518937A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
US20100113502A1 (en) * 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
US20070032385A1 (en) 2005-06-20 2007-02-08 Dunetz Joshua R Sustainable chemical processes
EA200802213A1 (ru) 2006-05-09 2009-10-30 Химекуэст Фармасьютикалз, Инк. Способы лечения заболеваний крови
LT2057156T (lt) 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
EP2130908A3 (en) 2006-08-29 2010-01-06 Reinnervate Limited Retinoid compounds and their use
WO2008124836A2 (en) 2007-04-10 2008-10-16 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
JP2010533712A (ja) 2007-07-19 2010-10-28 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物としてのベータカルボリン誘導体
WO2010002835A2 (en) * 2008-07-03 2010-01-07 Osteogenex, Inc. Vinpocetine and eburnamonine derivatives for promoting bone growth
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
ES2826950T3 (es) * 2009-05-27 2021-05-19 Ptc Therapeutics Inc Métodos para tratar cáncer y afecciones no neoplásicas
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B

Also Published As

Publication number Publication date
US10130617B2 (en) 2018-11-20
PE20160874A1 (es) 2016-09-04
SG11201509393VA (en) 2015-12-30
TN2015000516A1 (en) 2017-04-06
US9616050B2 (en) 2017-04-11
RS56678B1 (sr) 2018-03-30
ES2654161T3 (es) 2018-02-12
WO2014191726A1 (en) 2014-12-04
CN105229004B (zh) 2017-05-03
HUE035738T2 (en) 2018-05-28
HK1222859A1 (en) 2017-07-14
HRP20171961T1 (hr) 2018-02-09
CR20150629A (es) 2016-04-05
PH12015502615B1 (en) 2016-02-29
SMT201700589T1 (it) 2018-03-08
DK3004090T3 (en) 2018-01-08
RU2015151502A (ru) 2017-07-04
IL242559B (en) 2018-11-29
CY1120474T1 (el) 2019-07-10
MX361538B (es) 2018-12-10
NI201500167A (es) 2018-10-18
CA2911859A1 (en) 2014-12-04
PT3004090T (pt) 2017-12-22
EP3360875A1 (en) 2018-08-15
BR112015029455A2 (pt) 2017-07-25
CN105229004A (zh) 2016-01-06
BR112015029455A8 (pt) 2020-03-17
KR20160013198A (ko) 2016-02-03
US20160136140A1 (en) 2016-05-19
TW201536779A (zh) 2015-10-01
JP2016522835A (ja) 2016-08-04
EP3004090A1 (en) 2016-04-13
US20140357661A1 (en) 2014-12-04
SI3004090T1 (en) 2018-01-31
UY35590A (es) 2014-11-28
RU2664109C2 (ru) 2018-08-15
US20170326115A1 (en) 2017-11-16
AP2015008858A0 (en) 2015-11-30
US20190038607A1 (en) 2019-02-07
AU2014272856B2 (en) 2017-08-17
EP3004090B1 (en) 2017-10-25
JP6286031B2 (ja) 2018-02-28
ME02892B (me) 2018-04-20
US9155727B2 (en) 2015-10-13
LT3004090T (lt) 2018-01-10
AU2014272856A1 (en) 2015-11-26
TWI653235B (zh) 2019-03-11
PL3004090T3 (pl) 2018-02-28
RU2015151502A3 (OSRAM) 2018-03-23
DOP2015000274A (es) 2015-12-31
PH12015502615A1 (en) 2016-02-29
MX2015016428A (es) 2016-03-03

Similar Documents

Publication Publication Date Title
CL2015003491A1 (es) Compuestos químicos.
ECSP17073743A (es) Moduladores de k-ras
CL2015003089A1 (es) Heterociclos biciclicos como inhibidores de fgfr.
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2016002394A1 (es) Derivados de quinolina como inhibidores de smo
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
UY36075A (es) Derivados de tubulisina
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
TW201613911A (en) Heterocyclic compounds and uses thereof
MX378273B (es) Compuestos activos hacia bromodominios.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
TN2019000210A1 (en) Antitumoral compounds
CL2015002591A1 (es) Entidades químicas.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
PH12014502032A1 (en) Treatment of brain cancer